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Abstract: Colorectal cancer is the third most common cancer worldwide. Half of CRC patients develop
liver metastases during the course of the disease, with a 5-year survival rate close to zero in the absence
of therapy. Surgical resection remains the only possible curative option, and current guidelines recom-
mend adjuvant chemotherapy, resulting in a 5-year survival rate exceeding 50%. Neoadjuvant systemic
therapy is not indicated in cases with simple resection but should be offered to all patients with ex-
tensive bilobar disease. Personalised systemic treatment is essential to convert upfront non-resectable
lesions to resectable ones. Anatomical resections, non-anatomical resections and two-stage hepatectomies
can be performed though open or minimally invasive (laparoscopic or robotic) surgery. The extent of
a hepatic resection is limited by the risk of postoperative liver failure due to a too small liver remnant,
inflow or outflow obstruction or insufficient biliary drainage. About 75% of patients are diagnosed with
non-resectable liver metastases not amenable to a standard upfront resection. In recent years, effective
therapeutic approaches have revolutionised liver surgery and new strategies have enabled the conversion
of primarily non-resectable metastatic disease for resection. These strategies include oncological and
surgical therapies, as well as combinations of the two. From an oncological perspective, colorectal liver
metastasesnbsp; may be treated by systemic chemotherapy or immunotherapy, or selective intra-hepatic
arterial infusion chemotherapy, depending on the extent of the disease and the mutational status. In
surgery, we often apply two-stage strategies using portal vein occlusion, such as portal vein embolisation
or ligation, or complex two-stage hepatectomy such as associating liver partition and portal vein ligation
for staged hepatectomy. Other additive tools to reach curative resection are tumour ablations (electro-
poration, microwave or radiofrequency). The role of stereotactic radiation of liver metastases is not yet
well defined. Modern radiation techniques, including image guidance, breath hold and gating, were only
introduced for a larger patient population in recent years. Therefore, prospective studies with larger
patient cohorts are still pending. Over the last decade, liver transplantation has gained increasing at-
tention in selective cases of non-resectable colorectal liver metastases, with promising cohort studies, but
definitive recommendations must await the results of ongoing randomised controlled trials. The optimal
treatment of patients with colorectal liver metastases requires the timely association of various strategies,
and all cases must be discussed at multidisciplinary team conferences. While colorectal liver metastases
was a uniformly lethal condition a few decades ago, it has become amenable to curative therapies, with
excellent quality of life in many scenarios. This review reports on up-to-date treatment modalities and
their combinations in the treatment algorithm of colorectal liver metastases. nbsp; nbsp.
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Summary
Colorectal cancer is the third most common cancer world-
wide. Half of CRC patients develop liver metastases dur-
ing the course of the disease, with a 5-year survival rate
close to zero in the absence of therapy. Surgical resection
remains the only possible curative option, and current
guidelines recommend adjuvant chemotherapy, resulting
in a 5-year survival rate exceeding 50%. Neoadjuvant sys-
temic therapy is not indicated in cases with simple re-
section but should be offered to all patients with exten-
sive bilobar disease. Personalised systemic treatment is
essential to convert upfront non-resectable lesions to re-
sectable ones. Anatomical resections, non-anatomical re-
sections and two-stage hepatectomies can be performed
though open or minimally invasive (laparoscopic or robot-
ic) surgery.
The extent of a hepatic resection is limited by the risk of
postoperative liver failure due to a too small liver remnant,
inflow or outflow obstruction or insufficient biliary drainage.
About 75% of patients are diagnosed with non-resectable
liver metastases not amenable to a standard upfront re-
section. In recent years, effective therapeutic approach-
es have revolutionised liver surgery and new strategies
have enabled the conversion of primarily non-resectable
metastatic disease for resection. These strategies include
oncological and surgical therapies, as well as combina-
tions of the two. From an oncological perspective, col-
orectal liver metastases may be treated by systemic
chemotherapy or immunotherapy, or selective intra-hepat-
ic arterial infusion chemotherapy, depending on the ex-
tent of the disease and the mutational status. In surgery,
we often apply two-stage strategies using portal vein oc-
clusion, such as portal vein embolisation or ligation, or
complex two-stage hepatectomy such as associating liver
partition and portal vein ligation for staged hepatectomy.
Other additive tools to reach curative resection are tumour
ablations (electroporation, microwave or radiofrequency).
The role of stereotactic radiation of liver metastases is
not yet well defined. Modern radiation techniques, includ-
ing image guidance, breath hold and gating, were only in-
troduced for a larger patient population in recent years.
Therefore, prospective studies with larger patient cohorts
are still pending.
Over the last decade, liver transplantation has gained in-
creasing attention in selective cases of non-resectable col-
orectal liver metastases, with promising cohort studies, but
definitive recommendations must await the results of on-
going randomised controlled trials.
The optimal treatment of patients with colorectal liver
metastases requires the timely association of various
strategies, and all cases must be discussed at multidis-
ciplinary team conferences. While colorectal liver metas-
tases was a uniformly lethal condition a few decades ago,
it has become amenable to curative therapies, with excel-
lent quality of life in many scenarios. This review reports
on up-to-date treatment modalities and their combinations
in the treatment algorithm of colorectal liver metastases.
Keywords: colorectal liver metastases, CRLM, ALPPS,
associating liver partition and portal vein ligation for staged
hepatectomy, portal vein embolisation, PVE, portal vein
ligation, PVL
Introduction
In Switzerland, the age-standardised* incidence of new
cases of colon cancer between the years 2012-2016 was
45.8 for men and 29.7 for women. Compared to their age
group†, women with colon cancer are 9.7 times and men
15.9 times more likely to die, making it the third most com-
mon cause of cancer death in both sexes. (* The age-stan-
dardised incidence indicates the disease rate in a specif-
ic time period which would be expected in the considered
population if its age structure agreed with that of the stan-
dard population. † Standardised mortality rate per 100,000
inhabitants, European standard) [1].
Worldwide, an estimated 1.4 million new colorectal cancer
(CRC) cases are diagnosed every year, with 700,000 can-
cer deaths [2]. In 30–50% of patients with CRC the liver
is the predominant site for metastases, due to its immediate
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patients are diagnosed with synchronous liver metastases
[4, 7]. Without treatment the prognosis is dismal, with a
5-year survival rate of close to zero in historical data [8,
9]. Surgical resection of the metastatic tumours is the on-
ly curative treatment with a 5-year survival rate currently
exceeding 50% in most series [10, 11]. Unfortunately, only
25% of patients with colorectal liver metastases (CRLM)
qualify for resection at initial presentation. An increasing
number of patients may benefit from down-staging strate-
gies and eventually from a curative resection, often fol-
lowed by encouraging long-term outcomes. Combinations
of systemic chemotherapy and immunotherapy lead to cur-
rent response rates of over 50% for down-staging [12].
The combination of multimodal surgical and non-surgical
therapies offers the best chance for cure in patients with
CRLM. In this review, we present up-to-date, personalised
treatment options for the management of CRLM as prac-
ticed in our hepato-pancreato-biliary (HPB) centre in
Zurich (fig. 1)
Diagnostic work-up of colorectal liver metas-
tases
– Thoraco-abdominal computed tomography (CT) is part
of the standard imaging work-up.
– Magnetic resonance imaging (MRI) of the liver with he-
patobiliary contrast media shows the highest sensitivity
for CRLM.
– Positron emission tomography (PET)-CT can change
surgical management by detecting extrahepatic metas-
tases.
Medical history with physical examination, laboratory
tests including carcinoembryonic antigen, and abdomen ul-
trasound or a CT scan are usually available at the time
of referral to the surgeon. In our hepato-pancreato-biliary
centre in Zurich, Switzerland, we favour MRI of the liver
with hepatobiliary contrast media (Primovist, Bayer
Healthcare) to better detect liver metastases and surgically
relevant liver structures [13]. MRI with hepatobiliary con-
trast media shows the highest sensitivity for liver metas-
tases compared to contrast-enhanced CT or PET-CT, es-
pecially for lesions <1 cm and in patients who have
undergone chemotherapy [13, 14].
If the lesions appear resectable, PET-CT is performed to
detect extrahepatic disease [15]. The CT scan is crucial for
detecting pulmonary metastases. Lymph node metastases
and malignant disease in other organs may also be iden-
tified more easily with PET-CT [15]. With the use of ad-
ditional PET-CT in patients with resectable CRLM based
on CT scans, surgical management is changed in 10% of
patients and the rate of futile laparotomies can be reduced
[15].
Assessment of liver function
– Testing liver function prior to extended liver surgery, in-
cluding with bilirubin, factor V, international nor-
malised ratio and albumin tests, is recommended.
– Assessment of global liver function includes indocya-
nine green and hepatobiliary iminodiacetic acid testing.
Postoperative outcomes mainly depend on the size and
quality of the future liver remnant (FLR).
A preoperative assessment of the liver for volume and
function is important in order to predict the risk of post-
hepatectomy liver failure. Assessing and quantifying liver
function before surgery is still controversial because no
Figure 1: Flow chart of the treatment algorithm for colorectal metastases at the Swiss HPB Centre, Zurich, Switzerland.ALPPS = associating
liver partition and portal vein ligation for staged hepatectomy; TSH = classical two-stage hepatectomy; BSC = best supportive care; FLR = fu-
ture liver remnant; OLT = orthotopic liver transplantation; PVE = portal vein embolisation.
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single physiologic marker or score alone predicts postop-
erative liver failure.
There are three types of liver function tests: conventional
liver function tests, scoring systems and quantitative tests
[14]. The most widely used conventional liver function test
in clinical practice is assessment of the laboratory values,
including serum bilirubin, factor V and Quick test. The
Child-Pugh score, which was designed to assess the risk
of death in cirrhotic patients undergoing surgery for por-
tal hypertension, remains one of the most popular scoring
systems [16, 17]. This score applies only to patients with
cirrhosis. Patients with Child-Pugh score A usually have a
favourable course, while Child-Pugh score C represents a
contraindication for surgery. Surgery in Child-Pugh score
B cirrhotic patients must be discussed case by case.
Among the quantitative tests, the indocyanine green test is
correlated with liver function and the regenerative capaci-
ty of the liver [18–20]. This is a simple, non-invasive test
that can be performed at the bedside. Indocyanine green
test is a water-soluble dye that is injected via a peripher-
al venous access. It binds to proteins, and after being tak-
en up by hepatocytes, is excreted into the bile. The plasma
disappearance rate and the retention rate at 15 minutes are
measured by pulse spectrophotometry [21]. Plasma disap-
pearance rate values between 18% and 24% and a retention
rate at 15 minutes <15% may be indicators for normal liver
capacity and low-risk liver resection. Nevertheless, since
indocyanine green testing depends on the hepatocyte up-
take as well as excretion via the bile, chronic or acute liver
diseases may influence indocyanine green test results, lim-
iting their predictive value [21–26].
The LiMAx test is another method for investigating liver
function at the bedside. It is based on the assessment of
13C-methacetin metabolism by the liver-specific cy-
tochrome P450 1A2 system. 13C-methacetin is adminis-
tered intravenously and the ratio of 12CO2 to the
metabolised 13CO2 is measured by mask breathing. The
maximum liver function capacity is defined as the maxi-
mum value of the substrate conversion normalised to body
weight. A normal liver function is defined as ≥315 μg/kg/h.
Values between 140 and 315 μg/kg/h show limited hepatic
impairment, while 0–140 μg/kg/h means significant hepat-
ic injury. Preoperative performance in the LiMAx test can
help to determine the correct timing of hepatectomy after
previous chemotherapy, surgery or portal vein manipula-
tion, preventing post-hepatectomy liver failure [27]. How-
ever, both the indocyanine green and LiMAx tests assess
only global liver function, and not the function of the FLR
specifically.
Exact FLR function can, however, be assessed with a he-
patobiliary iminodiacetic acid scan. This is an imaging
modality used to investigate metabolic diseases of the liv-
er, as well as excretion dynamics of the gallbladder and
bile ducts. A radioactive tracer is injected, taken up by
the bile-producing cells and excreted into the biliary tree,
which drains into the duodenum. Imaging is obtained by a
γ camera and shows liver function for the whole liver as
well as for regions or parts of interest, such as the FLR
[28].
Quantitative tests evaluate the metabolism and the clear-
ance of different substrates that are mostly or entirely
cleared by the liver. It is important to note that quantitative
tests provide more reliable information on the preoperative
liver function than on the postoperative liver function be-
cause they address one of the liver’s true processes (i.e.,
galactose elimination or bile acid clearance). While in pa-
tients with normal liver function the suggested limits for
safe resection range from 20 to 30% FLR volume, most
guidelines indicate 30% [10, 29].
Perioperative systemic chemotherapy for col-
orectal liver metastases
– Down-staging of non-resectable CRLM can be
achieved with personalised systemic chemotherapy.
– Perioperative chemotherapy for resectable CRLM must
be restricted to situations with an unfavourable risk
profile.
Systemic chemotherapy is an integral part of the multi-
modal management of CRLM. Perioperative chemothera-
py targets micro-metastatic disease in order to reduce the
risk of recurrence following resection. In more advanced
situations, preoperative chemotherapy aims to convert up-
front non-resectable CRLM to resectable ones. Modern
personalised combination chemotherapy for metastatic
CRC has improved substantially, with current response
rates of over 50%, up from approximately 10% with a sin-
gle-agent treatment prior to 2000.
Upfront resectable CRLM with a favourable risk profile
must undergo upfront resection followed by adjuvant
chemotherapy, particularly when the patient has not re-
ceived any previous adjuvant treatment [12]. In less
favourable risk constellations, such as with synchronous
metastases or a short interval between primary tumour
resection and systemic tumour recurrence, perioperative
treatment with 6 months of FOLFOX (leucovorin, fluo-
rouracil, oxaliplatin) or CAPOX (capecitabine, oxaliplatin)
split evenly before and after surgery, based on the pivotal
EPOC trial, is a widely used option [30]. Median overall
survival improved from 47 months in the surgery only
group to 62 months when adjuvant chemotherapy followed
the surgery [31].
In patients with technically non-resectable CRLM,
chemotherapy aiming to render them resectable prior to
surgery is essential. Conversion treatment aims for max-
imum tumour shrinkage and typically involves combina-
tions of chemotherapy doublets or triplets with monoclonal
antibodies (anti-endothelial growth factor receptor [anti-
EGFR], anti-vascular endothelial growth factor [anti-
VEGF]). Treatment is personalised, based on molecular
profile and biological criteria, most prominently primary
tumour sidedness [10]. Reported success rates of conver-
sion treatment are as high as 30% [9, 10]. The optimal
duration of conversion therapy has not been established;
maximum tumour shrinkage in metastatic CRC is typically
achieved after 12–16 weeks of chemotherapy. In these sit-
uations, accumulation of toxicity in the liver due to pro-
longed application of intensified chemotherapy protocols
poses a significant risk. It is important to note that modern
perioperative treatment, as an essential part of multimodal-
ity treatment of CRLM, must be personalised: guided by
established principles but highly adaptable to individual
constellations.
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Molecular subtyping of metastatic CRC is evolving. At
least seven clinically relevant subgroups of metastatic
CRC exist in clinical routine and impact on perioperative
conversion treatment [10]. CRLM from left-sided wild-
type tumours (wild-type = absence of a common driver
oncogene alteration such as the KRAS, NRAS and BRAF
mutations or HER2/neu amplification) should always be
treated with chemotherapy plus anti-EGFR antibodies,
while CRLM from right-sided wild-type tumours do not
appear to benefit from anti-EGFR and are treated with
anti-VEGFR plus chemotherapy. Moreover, CRLM from
right-sided primaries are associated with inferior prognosis
and show inferior response to conversion treatment com-
pared to CRLM from left-sided primaries. BRAF-V600E
mutant metastatic CRC show aggressive biological behav-
iour and very poor prognosis following liver resection. The
highly immunogenic dMMR/MSI-H subgroup show ex-
cellent responses to immune checkpoint inhibitors, while
HER2-amplified metastatic CRCs show encouraging re-
sults with HER2 blocking agents. The largest molecular
subgroup of KRAS/NRAS mutant metastatic CRC are re-
sistant to anti-EGFR treatment and are commonly treated
with a chemotherapy doublet or triplet anti-VEGF-receptor
(bevacizumab) for conversion treatment.
In selected cases, locoregional chemotherapeutic treatment
can be combined with systemic treatment to maximise tu-
mour response. Hepatic artery infusion chemotherapy via
a pump, combining systemic and locoregional treatment in
the preoperative setting, was introduced in 1969. Continu-
ous hepatic artery infusion chemotherapy with floxuridine
in combination with systemic chemotherapy has been as-
sociated with satisfactory conversion rates in selected cas-
es of non-resectable CRLM [29].
Surgical strategies for synchronous colorectal
liver metastases
– Symptomatic primary tumours in the colon or rectum
should be treated first with high priority.
– In asymptomatic primary CRC, the liver first approach
is preferred.
Several surgical strategies may be considered to address
synchronous CRLM. (1) The classic approach is to treat
the primary colon or rectum tumour first followed by the
liver metastasis in a second step, in combination with vari-
able applications of perioperative chemotherapy. This
strategy remains the gold standard in patients with symp-
tomatic primary tumours. (2) Simultaneous resection com-
bining resection of the primary tumour and the liver metas-
tases. This one-step procedure is feasible and has been
reported with success in many articles, usually in cases
with minimal liver involvement (e.g., <3 segments) [32,
33]. This method can often be done with a minimal inva-
sive approach (laparoscopic, robotic) [33]. (3) The “liver
first approach” involves resecting the CRLM upfront and
is routinely associated with neoadjuvant chemotherapy
[10]. It is the preferred approach at our hepato-pancreato-
biliary centre in Zurich, where we often deal with major
spread of the liver tumour. We often start with systemic
chemotherapy over 3 months, followed by restaging and,
in the case of tumour response, eventually a two-stage he-
patectomy. A few weeks later, the excision of the primary
colon tumour completes the complete removal of tumour
disease [10, 29, 34].
Convincing data on survival advantages between colon
first and liver first strategies are lacking [32]. In the context
of hepatic resections, anatomical resections are defined as
resections of one or more anatomic liver segments [35].
For example, a right hemi-hepatectomy involves the re-
section of segments V to VIII. Non-anatomical resections,
also named parenchymal-sparing hepatectomies, aim to
achieve oncological resections with a minimum sufficient
margin while preserving as much liver parenchyma as pos-
sible. It has been suggested that a 1-mm oncological mar-
gin is sufficient in CRLM [36]. In our centre, we accept on-
ly resection with a 0.5-cm tumour-free margin, which we
achieve, when necessary, with additional application of ra-
diofrequency on the margin (e.g., Aquamantys, Medtron-
ics) [37].
Strategies to increase the future liver remnant
– Two-stage hepatectomy is recommended if the FLR is
less than 25–30%.
– A larger FLR might be required in injured liver
parenchyma.
– Strategies to increase the FLR are based mainly on oc-
clusion of the portal vein.
A number of strategies have been developed to increase
the FLR. (fig. 2, fig. 3c–h). The first human application
of such a strategy, portal vein ligation of the tumour-bear-
ing lobe during surgery, was described in 1975 [38]. Portal
vein ligation was thought to induce tumour regression in
the affected lobe. But portal vein occlusion of one liver
lobe leads to compensatory hypertrophy of the contralat-
eral, non-occluded FLR, which may ultimately enable
surgery in cases where the FLR does not yet have the nec-
essary volume/function to allow resection of the diseased
part of the liver [38, 39].
In a classical two-stage procedure, the portal branch to the
diseased liver lobe is ligated intra-operatively and the re-
section can be performed at a later stage, when the FLR
has reached its necessary volume. Nevertheless, this might
take several weeks and the waiting time cannot be justified
for certain tumour growth patterns. Therefore, a concept
termed associating liver partition and portal vein ligation
for staged hepatectomy (ALPPS) was introduced by a
group from Regensburg, Germany in 2007. ALPPS is a
combination of portal vein ligation and in-situ liver
parenchyma transection performed during the first stage.
Initial experience suggested that ALPPS leads to faster liv-
er regeneration (7–10 days) compared to portal vein em-
bolisation or ligation (4–12 weeks) (fig. 2, fig. 3f–h) [38].
The mechanisms behind this enhanced stimulation and ac-
celerated regenerative response of the liver after parenchy-
mal liver transection combined with portal vein ligation are
currently being investigated extensively [40]. Advances in
patient selection and in modalities to assess liver function,
as well as modifications to the ALPPS technique, have led
to a significant decrease in morbidity and mortality in pa-
tients undergoing ALPPS [41–44]. Morbidity and mortali-
ty for ALPPS are currently comparable with conventional
major hepatectomy procedures [45].
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Laparoscopic and robotic liver surgery for col-
orectal liver metastases
– Laparoscopic liver resection for CRLM is associated
with significantly fewer postoperative complications
compared to open surgery.
– Laparoscopic liver resection is cost-effective and onco-
logically adequate.
– Robotic technology is currently used for minor as well
as major liver surgeries, including ALPPS, and may
rapidly become the standard approach.
Minimally invasive resection of CRLM with a laparoscop-
ic or robotic approach is gaining increasing acceptance,
supported by proven short-term postoperative benefits [46]
and reported equal oncologic outcomes compared to open
surgery. The first randomised controlled trial for open vs
laparoscopic liver surgery, from Norway (COMET trial),
showed that laparoscopic liver resection for CRLM is as-
sociated with significantly fewer postoperative complica-
tions compared to open surgery [47]. Moreover, a sub-
group analysis of patients undergoing laparoscopic
resection of CRLM located in the postero-superior seg-
ments (difficult access by any approach) revealed a shorter
hospital stay and similar perioperative outcomes compared
to open resection [48]. Data accumulated into a large co-
hort of patients from expert centres showed that laparo-
scopic liver resection is cost-effective [46, 47, 49, 50]. The
ORANGE II PLUS trial, currently recruiting patients, will
be the first randomised, multicentre study to compare open
vs. laparoscopic hemi-hepatectomy. At our hepato-pancre-
ato-biliary centre, we currently favour robot-assisted liver
resection, particularly for tumours located in the difficult
right posterior liver segments. Robotic surgery offers a bet-
ter degree of freedom in moving the instruments, better vi-
sion and better precision [51]. Exponential growth of the
use of minimally invasive liver surgery in the past few
years mandates the continuous development of necessary
guidelines.
Figure 3: Strategies to increase the future liver remnant. (a) Parenchyma with bilobar CRLM before wedge resections (b) After wedge resec-
tions of small peripheral CRLM (c) One-stage liver surgery with portal vein embolisation on the lobe to be removed. (d) Hypertrophy of the
FLR. (e) Removal of the embolised right lobe. (f) Bilobar CRLM before surgery g) Open ligation on the right portal vein branch and cleaning of
the FLR. (h) Removal of the deportalised lobe. Illustration: Carol De Simio-Hilton.
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Local therapies for non-resectable liver metas-
tases
Ablative therapies
Radiofrequency and microwave ablation are the most fre-
quent ablative thermal modalities (fig. 4). These tech-
niques allow CT- or ultrasound-guided localisation and
precise open or percutaneous destruction of central liver
tumours close to main structures not accessible for surgery.
Microwave ablation induces more coagulation necrosis in
a shorter time than radiofrequency ablation. Microwave
ablation is nowadays used more frequently as it is more ef-
fective when treating a small number of tumours (<5) of
limited size (<3 cm), showing low rates of post-interven-
tional complications (1–3%) and excellent local tumour
control [52]. However, long-term oncological results for
microwave ablation fail to show superiority over surgical
resection for small tumours, and have clearly worse out-
comes (66% local recurrence rate) for CRLM larger than
3 cm [53]. An ongoing randomised controlled trial from
the COLLISION trial group may answer the question of
whether or not ablation is inferior to surgery for lesions
≤3 cm. Ablation could be a promising alternative, with re-
duced morbidity and mortality, a shorter hospital stay and
economic benefits. Unfortunately, the applicability of ra-
diofrequency and microwave ablation for tumours close to
large vessels is limited due to the “heat sink effect” (fig. 4).
Irreversible electroporation is a newer, non-thermal abla-
tive option to eliminate lesions involving important vascu-
lar or biliary structures. Irreversible electroporation does
not affect the extracellular matrix and the integrity of the
biliary and vascular structures is preserved, enabling cellu-
lar recolonisation. However, the high-voltage current puls-
es used generate excitation of skeletal and cardiac muscle.
General anaesthesia with neuromuscular blockade is there-
fore necessary during the procedure, and cardiac arrhyth-
mia is an absolute contraindication for irreversible electro-
poration. The exact placement of multiple “soft” probes is
challenging and consistently time-consuming [54].
Stereotactic external radiotherapy / stereotactic body
radiotherapy
Historically, external beam radiotherapy has played a mi-
nor role in the treatment of CRLM because of the low ra-
diation tolerance of the liver [55]. Technological advances
in the past few decades have enabled the conformal deliv-
ery of high radiation doses to a defined lesion whilst spar-
ing functional liver tissue. Stereotactic body radiotherapy,
a form of high-precision radiotherapy in which ablative ra-
diation doses are delivered non-invasively in 1 to 10 am-
Figure 4: Radiofrequency (RFA) and microwave ablation (MWA) are the most frequently used ablative thermal modalities. Illustration: Carol
De Simio-Hilton.
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bulatory treatment sessions, was shown to be efficacious,
with 2-year local control rates ranging from 59% to 84%,
while having a favourable toxicity profile [56, 57]. No-
tably, most patients offered stereotactic body radiotherapy
had serious comorbidities and were considered medically
unfit for major liver surgery or had non-resectable metas-
tases. When evaluating the optimal treatment modality for
local therapy of non-resectable liver metastases, tumour
size is an important factor: subgroup results report high-
er local control for stereotactic body radiotherapy than for
radiofrequency ablation in metastases >2 cm, but not for
those ≤2 cm [58]. Accordingly, the European Society for
Medical Oncology consensus guidelines propose a “tool-
box” concept [12], where stereotactic body radiotherapy
should only be considered for patients with a contraindi-
cation for or who refuse an invasive procedure, as well as
for patients with large liver metastases or metastases lo-
cated at central biliary or vascular structures. The optimal
integration of stereotactic body radiotherapy into modern
multimodal treatment concepts remains to be defined. The
Figure 2: Treatment algorithm for an individual patient with bilobar
colorectal liver metastasis at the Swiss HPB Centre, Zurich,
Switzerland. (a) Start of chemotherapy. (b–d) MRI (Primovist) glob-
al reduction of all lesions. Lesion: 22.4 cm3, FLR right liver: 58.69%
/ 742 cm3. (e) Intraoperative situs ALPPS Stage I. (f) MRI (Primo-
vist) one week after Stage I: clean FLR (right lobe) with 901 cm3
and adequate compensatory overgrowth before Stage II. g) Intra-
operative situs ALLPS Stage II. (h) Anatomical specimen after he-
patectomy. (i–k) 6 months after surgery, CRLM reappears. (l) hy-
pervascucularised CRLM poor in contrast with selective probing of
the right hepatic artery with a 2.7F catheter. Selective internal radi-
ation therapy (SIRT) for recurrent lesion after 7 months.
recent introduction of MRI-guided radiotherapy into clini-
cal routine, allowing for direct visualisation of the tumour
and healthy tissues before each session and live-tracking of
the tumour during treatment, may foster better integration
of stereotactic body radiotherapy into management of liver
metastases [59].
Selective internal radiation therapy
Selective internal radiation therapy is an internal, localised
radiotherapy using Yttrium-90 (90Y, β-particles), which has
a short radiation range (1 cm) and a half-life of <3 days
(see fig. 1 for illustration). The radioactive isotope is in-
fused into either resin or glass particles. Using an angiogra-
phy targeting the branch of the hepatic artery supplying the
tumour, selective administration of the radioactive isotope
is achieved by infusion of 90Y microspheres through the se-
lectively placed catheter. Complete response after selective
internal radiation therapy is rarely achieved for CRLM, but
stable disease is seen in many patients [60, 61]. High pre-
treatment tumour volume has been shown to be an inde-
pendent predictor of inferior overall survival after selec-
tive internal radiation therapy. A recently published joint
analysis [62] of three studies with 549 patients assigned
to FOLFOX alone and 554 patients assigned FOLFOX
plus selective internal radiation therapy [62] revealed that
local selective internal radiation therapy significantly re-
duced the incidence of radiological progression within the
liver, but that selective internal radiation therapy did not
have an influence on progression-free survival or median
overall survival (23 vs 23 months). Additionally, toxicity
was significantly increased in the selective internal radia-
tion therapy group. Therefore, routine integration of selec-
tive internal radiation therapy into FOLFOX-based first-
line chemotherapy cannot be recommended for metastatic
CRC at this time.
Liver transplantation for non-resectable col-
orectal liver metastases
– For non-resectable CRLM, orthotopic liver transplan-
tation provides better survival results compared to pal-
liative chemotherapy.
– Orthotopic liver transplantation for non-resectable
CRLM is only for carefully selected patients, such as
those with resection of the primary more than 18 m, to-
tal hepatic tumour diameter not more than 6 cm, carci-
noembryonic antigen <80 μg/l, a BRAF wild type and
stable disease under chemotherapy.
A possible therapy for end-stage liver diseases and selected
primary or metastatic liver tumours is an orthotopic liver
transplantation. However, strict criteria must be met to se-
cure a reasonable outcome after orthotopic liver transplan-
tation. Life-long immunosuppression may enhance the risk
of tumour recurrence, with poorer outcomes [63]. The first
seven human orthotopic liver transplants were performed
for liver malignancies in the years 1963 and 1964. How-
ever, only two of these were for CRLM [64]. From 1985
to 1994, the overall survival after orthotopic liver trans-
plantation reached 52–65%. Due to an increasing shortage
of organs, indications for orthotopic liver transplantation
because of liver malignancies had to be strongly justified,
leading to more restrictive indications in many guidelines
[63, 65, 66].
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Orthotopic liver transplantation was abandoned for many
types of tumours, including CRLM, in the 1990s due to
a very poor 5-year survival rate of only 12–18% [66–68].
Since then, the oncologic management of CRLM has
evolved dramatically, with the availability of new im-
munosuppressive agents such as mTOR (mammalian tar-
get of rapamycin) inhibitors conferring antineoplastic ef-
fects [67–69]. These advances encouraged a Norwegian
group to re-introduce orthotopic liver transplantation indi-
cation in selected cases of CRLM. Such a study was pos-
sible in Norway because the average waiting time for a
cadaveric graft is <1 month. The surfeit of donor livers
has stimulated a study investigating the potential role of
orthotopic liver transplantation in long-term survival for
non-resectable CRLM [68]. The 5-year survival rate was
surprisingly high, at 60% (21 patients). Nevertheless, re-
currence was seen in 19 out of 21 patients after a median
of 6 months. Recurrent tumours were treated with surgery
or local ablation. After a median of 27 months, 33% of pa-
tients were tumour free. In this study, first-line chemother-
apy for non-resectable CRLM demonstrated a 5-year sur-
vival rate of 9%, while patients undergoing orthotopic liver
transplantation had a 5-year survival rate of 56%. Disease-
free survival did not differ between these two groups. De-
spite these spectacular results in Norway, widespread use
of orthotopic liver transplantation in other countries is cur-
rently compromised due to donor shortages. At the Univer-
sity Hospital Zurich, we do offer orthotopic liver transplan-
tation for selected patients, mostly those with tumours that
have been well-controlled by chemotherapy for at least 6
months. Due to the lack of available cadaveric grafts, we
preferentially offer living donor liver transplantation.
Conclusion
In recent years, the management of CRLM has seen several
advances, including novel imaging and molecular modali-
ties which can be used to adjust treatment more precisely
and in a more personalised manner, and which are routine-
ly discussed at our weekly multidisciplinary team meet-
ings. Different strategies for the resection of CRLM, like
the classic, simultaneous and liver first approaches, are es-
tablished for different, well-defined scenarios [10]. In par-
ticular cases, we have opted for aggressive approaches,
sometimes combining two-stage procedures like ALPPS to
enable curative resection in patients with very small, in-
tra-arterial chemotherapy, and eventually orthotopic liver
transplantation.
In a rapidly evolving field, different regimens of systemic
and local chemotherapy, including different antibodies de-
pending on the mutational status, are used to convert non-
resectable hepatic metastatic disease into a resectable sit-
uation, providing a chance of cure. Additive tools such as
thermal and non-thermal ablative procedures are essential
for individually tailoring CRLM treatment options, espe-
cially when surgical interventions alone are limited due to
proximity of tumours to central vascular or biliary struc-
tures. The combination of ablation and surgery is often
chosen when aiming for a parenchyma-sparing procedure
with respect to the disease course and liver tissue quality.
Stereotactic radiation treatment of CRLM offers a non-in-
vasive treatment in tumours greater than 3 cm in size, even
in high-risk situations or sick patients, with acceptable re-
sults and limited impact on quality of life.
Because many modern, individually tailored multimodal
concepts require a strong and demanding adherence of pa-
tients to long-term therapies, doctors must lead compre-
hensive, interdisciplinary conversations with patients and
their families in order to make adequate decisions in the
fight against CRLM.
Acknowledgements
The authors would like to thank Carol De Simio-Hilton for her won-
derful illustrations.
Disclosure statement
No financial support and no other potential conflicts of interest rele-
vant to this article was reported.
References
1 https://www.bfs.admin.ch/bfs/de/home/statistiken/gesundheit/gesund-
heitszustand/krankheiten/krebs/spezifische.html July, 20th, 2020.
2 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Glob-
al cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. Pub-
lished online February 06, 2015. doi: http://dx.doi.org/10.3322/
caac.21262. PubMed.
3 Poston GJ, Adam R, Alberts S, Curley S, Figueras J, Haller D, et al. On-
coSurge: a strategy for improving resectability with curative intent in
metastatic colorectal cancer. J Clin Oncol. 2005;23(28):7125–34. Pub-
lished online September 30, 2005. doi: http://dx.doi.org/10.1200/
JCO.2005.08.722. PubMed.
4 Slesser AA, Simillis C, Goldin R, Brown G, Mudan S, Tekkis PP. A
meta-analysis comparing simultaneous versus delayed resections in pa-
tients with synchronous colorectal liver metastases. Surg Oncol.
2013;22(1):36–47. Published online December 21, 2012. doi:
http://dx.doi.org/10.1016/j.suronc.2012.11.002. PubMed.
5 Hackl C, Neumann P, Gerken M, Loss M, Klinkhammer-Schalke M,
Schlitt HJ. Treatment of colorectal liver metastases in Germany: a ten-
year population-based analysis of 5772 cases of primary colorectal ade-
nocarcinoma. BMC Cancer. 2014;14(1):810. doi: http://dx.doi.org/
10.1186/1471-2407-14-810. PubMed.
6 Manfredi S, Lepage C, Hatem C, Coatmeur O, Faivre J, Bouvier AM.
Epidemiology and management of liver metastases from colorectal can-
cer. Ann Surg. 2006;244(2):254–9. doi: http://dx.doi.org/10.1097/
01.sla.0000217629.94941.cf. PubMed.
7 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier
P, et al.; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Re-
search UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirur-
gischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian
Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de
Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOL-
FOX4 and surgery versus surgery alone for resectable liver metastases
from colorectal cancer (EORTC Intergroup trial 40983): a randomised
controlled trial. Lancet. 2008;371(9617):1007–16. doi: http://dx.doi.org/
10.1016/S0140-6736(08)60455-9. PubMed.
8 Wagner JS, Adson MA, Van Heerden JA, Adson MH, Ilstrup DM. The
natural history of hepatic metastases from colorectal cancer. A compari-
son with resective treatment. Ann Surg. 1984;199(5):502–8. doi:
http://dx.doi.org/10.1097/00000658-198405000-00002. PubMed.
9 Lehmann K, Rickenbacher A, Weber A, Pestalozzi BC, Clavien PA.
Chemotherapy before liver resection of colorectal metastases: friend or
foe? Ann Surg. 2012;255(2):237–47. Published online November 02,
2011. doi: http://dx.doi.org/10.1097/SLA.0b013e3182356236. PubMed.
10 Petrowsky H, Fritsch R, Guckenberger M, De Oliveira ML, Dutkowski
P, Clavien PA. Modern therapeutic approaches for the treatment of ma-
lignant liver tumours. Nat Rev Gastroenterol Hepatol.
2020;17(12):755–72; Epub ahead of print. doi: http://dx.doi.org/
10.1038/s41575-020-0314-8. PubMed.
11 Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier
P, et al.; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Re-
search UK; Arbeitsgruppe Lebermetastasen und–tumoren in der Chirur-
gischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian
Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de
Cancérologie Digestive (FFCD). Perioperative FOLFOX4 chemothera-
py and surgery versus surgery alone for resectable liver metastases from
colorectal cancer (EORTC 40983): long-term results of a randomised,
controlled, phase 3 trial. Lancet Oncol. 2013;14(12):1208–15. doi:
http://dx.doi.org/10.1016/S1470-2045(13)70447-9. PubMed.
Review article: Biomedical intelligence Swiss Med Wkly. 2021;151:w20390
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 8 of 10
12 Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH,
Aderka D, et al. ESMO consensus guidelines for the management of pa-
tients with metastatic colorectal cancer. Ann Oncol.
2016;27(8):1386–422. Published online July 07, 2016. doi:
http://dx.doi.org/10.1093/annonc/mdw235. PubMed.
13 Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver
metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a
meta-analysis of prospective studies including patients who have not
previously undergone treatment. Radiology. 2010;257(3):674–84. Pub-
lished online September 11, 2010. doi: http://dx.doi.org/10.1148/radi-
ol.10100729. PubMed.
14 Chu QD, Volmer CM, Zibari GB, Orloff SL, Williams M, Gimenez ME,
eds. Hepato-Pancreato-Biliary and Transplant Surgery: Practical Man-
agement of Dilemmas. AHPBA: Beaux Books; 2018.
15 Moulton CA, Gu CS, Law CH, Tandan VR, Hart R, Quan D, et al. Ef-
fect of PET before liver resection on surgical management for colorectal
adenocarcinoma metastases: a randomized clinical trial. JAMA.
2014;311(18):1863–9. Published online May 16, 2014. doi:
http://dx.doi.org/10.1001/jama.2014.3740. PubMed.
16 Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R.
Transection of the oesophagus for bleeding oesophageal varices. Br J
Surg. 1973;60(8):646–9. Published online August 01, 1973. doi:
http://dx.doi.org/10.1002/bjs.1800600817. PubMed.
17 Child CG (ed.) The Liver and Portal Hypertension. Philadelphia and
London: W. B. Saunders Co. Ltd; 1964.
18 Zipprich A, Kuss O, Rogowski S, Kleber G, Lotterer E, Seufferlein T, et
al. Incorporating indocyanin green clearance into the Model for End
Stage Liver Disease (MELD-ICG) improves prognostic accuracy in in-
termediate to advanced cirrhosis. Gut. 2010;59(7):963–8. Published on-
line June 29, 2010. doi: http://dx.doi.org/10.1136/gut.2010.208595.
PubMed.
19 Stauber RE, Wagner D, Stadlbauer V, Palma S, Gurakuqi G, Kniepeiss
D, et al. Evaluation of indocyanine green clearance and model for end-
stage liver disease for estimation of short-term prognosis in decompen-
sated cirrhosis. Liver Int. 2009;29(10):1516–20. doi: http://dx.doi.org/
10.1111/j.1478-3231.2009.02104.x. PubMed.
20 Lisotti A, Azzaroli F, Buonfiglioli F, Montagnani M, Cecinato P, Turco
L, et al. Indocyanine green retention test as a noninvasive marker of por-
tal hypertension and esophageal varices in compensated liver cirrhosis.
Hepatology. 2014;59(2):643–50. Published online September 17, 2013.
doi: http://dx.doi.org/10.1002/hep.26700. PubMed.
21 de Liguori Carino N, O’Reilly DA, Dajani K, Ghaneh P, Poston GJ, Wu
AV. Perioperative use of the LiMON method of indocyanine green elim-
ination measurement for the prediction and early detection of post-hepa-
tectomy liver failure. Eur J Surg Oncol. 2009;35(9):957–62. doi:
http://dx.doi.org/10.1016/j.ejso.2009.02.003. PubMed.
22 Ray S, Mehta NN, Golhar A, Nundy S. Post hepatectomy liver failure -
A comprehensive review of current concepts and controversies. Ann
Med Surg (Lond). 2018;34(34):4–10. doi: http://dx.doi.org/10.1016/
j.amsu.2018.08.012. PubMed.
23 Ge PL, Du SD, Mao YL. Advances in preoperative assessment of liver
function. Hepatobiliary Pancreat Dis Int. 2014;13(4):361–70. Published
online August 08, 2014. doi: http://dx.doi.org/10.1016/
S1499-3872(14)60267-8. PubMed.
24 Hoekstra LT, de Graaf W, Nibourg GA, Heger M, Bennink RJ, Stieger
B, et al. Physiological and biochemical basis of clinical liver function
tests: a review. Ann Surg. 2013;257(1):27–36. Published online July 28,
2012. doi: http://dx.doi.org/10.1097/SLA.0b013e31825d5d47. PubMed.
25 Mizuguchi T, Kawamoto M, Meguro M, Hui TT, Hirata K. Preoperative
liver function assessments to estimate the prognosis and safety of liver
resections. Surg Today. 2014;44(1):1–10. Published online March 12,
2013. doi: http://dx.doi.org/10.1007/s00595-013-0534-4. PubMed.
26 Du ZG, Li B, Wei YG, Yin J, Feng X, Chen X. A new scoring system
for assessment of liver function after successful hepatectomy in patients
with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.
2011;10(3):265–9. Published online June 15, 2011. doi:
http://dx.doi.org/10.1016/S1499-3872(11)60044-1. PubMed.
27 Lock JF, Westphal T, Rubin T, Malinowski M, Schulz A, Jara M, et al.
LiMAx Test Improves Diagnosis of Chemotherapy-Associated Liver In-
jury Before Resection of Colorectal Liver Metastases. Ann Surg Oncol.
2017;24(9):2447–55. Published online May 19, 2017. doi:
http://dx.doi.org/10.1245/s10434-017-5887-2. PubMed.
28 Bennink RJ, Dinant S, Erdogan D, Heijnen BH, Straatsburg IH, van Vli-
et AK, et al. Preoperative assessment of postoperative remnant liver
function using hepatobiliary scintigraphy. J Nucl Med.
2004;45(6):965–71. PubMed.
29 Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer
liver surgery and partial liver transplantation. N Engl J Med.
2007;356(15):1545–59. Published online April 13, 2007. doi:
http://dx.doi.org/10.1056/NEJMra065156. PubMed.
30 Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachel-
lier P, et al.; Association Française de Chirurgie. Surgical resection of
colorectal carcinoma metastases to the liver. A prognostic scoring sys-
tem to improve case selection, based on 1568 patients. Cancer.




31 Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Ad-
juvant chemotherapy after potentially curative resection of metastases
from colorectal cancer: a pooled analysis of two randomized trials. J
Clin Oncol. 2008;26(30):4906–11. Published online September 17,
2008. doi: http://dx.doi.org/10.1200/JCO.2008.17.3781. PubMed.
32 Baltatzis M, Chan AK, Jegatheeswaran S, Mason JM, Siriwardena AK.
Colorectal cancer with synchronous hepatic metastases: Systematic re-
view of reports comparing synchronous surgery with sequential bowel-
first or liver-first approaches. Eur J Surg Oncol. 2016;42(2):159–65. doi:
http://dx.doi.org/10.1016/j.ejso.2015.11.002. PubMed.
33 de Haas RJ, Adam R, Wicherts DA, Azoulay D, Bismuth H, Vibert E, et
al. Comparison of simultaneous or delayed liver surgery for limited syn-
chronous colorectal metastases. Br J Surg. 2010;97(8):1279–89. Pub-
lished online June 26, 2010. doi: http://dx.doi.org/10.1002/bjs.7106.
PubMed.
34 Mentha G, Majno PE, Andres A, Rubbia-Brandt L, Morel P, Roth AD.
Neoadjuvant chemotherapy and resection of advanced synchronous liver
metastases before treatment of the colorectal primary. Br J Surg.
2006;93(7):872–8. Published online May 04, 2006. doi:
http://dx.doi.org/10.1002/bjs.5346. PubMed.
35 Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, et
al. Comparison between hepatic wedge resection and anatomic resection
for colorectal liver metastases. J Gastrointest Surg. 2006;10(1):86–94.
Published online December 22, 2005. doi: http://dx.doi.org/10.1016/
j.gassur.2005.07.022. PubMed.
36 Hamady ZZ, Lodge JP, Welsh FK, Toogood GJ, White A, John T, et al.
One-millimeter cancer-free margin is curative for colorectal liver metas-
tases: a propensity score case-match approach. Ann Surg.
2014;259(3):543–8. Published online June 05, 2013. doi:
http://dx.doi.org/10.1097/SLA.0b013e3182902b6e. PubMed.
37 Hammond JS, Muirhead W, Zaitoun AM, Cameron IC, Lobo DN. Com-
parison of liver parenchymal ablation and tissue necrosis in a cadaveric
bovine model using the Harmonic Scalpel, the LigaSure, the Cavitron
Ultrasonic Surgical Aspirator and the Aquamantys devices. HPB (Ox-
ford). 2012;14(12):828–32. doi: http://dx.doi.org/10.1111/
j.1477-2574.2012.00547.x. PubMed.
38 Eshmuminov D, Raptis DA, Linecker M, Wirsching A, Lesurtel M,
Clavien PA. Meta-analysis of associating liver partition with portal vein
ligation and portal vein occlusion for two-stage hepatectomy. Br J Surg.
2016;103(13):1768–82. Published online September 17, 2016. doi:
http://dx.doi.org/10.1002/bjs.10290. PubMed.
39 de Santibañes E, Clavien PA. Playing Play-Doh to prevent postoperative
liver failure: the “ALPPS” approach. Ann Surg. 2012;255(3):415–7.
Published online February 15, 2012. doi: http://dx.doi.org/10.1097/
SLA.0b013e318248577d. PubMed.
40 Langiewicz M, Schlegel A, Saponara E, Linecker M, Borger P, Graf R,
et al. Hedgehog pathway mediates early acceleration of liver regenera-
tion induced by a novel two-staged hepatectomy in mice. J Hepatol.
2017;66(3):560–70. Published online October 25, 2016. doi:
http://dx.doi.org/10.1016/j.jhep.2016.10.014. PubMed.
41 Petrowsky H, Györi G, de Oliveira M, Lesurtel M, Clavien PA. Is par-
tial-ALPPS safer than ALPPS? A single-center experience. Ann Surg.
2015;261(4):e90–2. Published online February 24, 2015. doi:
http://dx.doi.org/10.1097/SLA.0000000000001087. PubMed.
42 Moris D, Ronnekleiv-Kelly S, Kostakis ID, Tsilimigras DI, Beal EW,
Papalampros A, et al. Operative Results and Oncologic Outcomes of As-
sociating Liver Partition and Portal Vein Ligation for Staged Hepatecto-
my (ALPPS) Versus Two-Stage Hepatectomy (TSH) in Patients with
Unresectable Colorectal Liver Metastases: A Systematic Review and
Meta-Analysis. World J Surg. 2018;42(3):806–15. Published online Au-
gust 12, 2017. doi: http://dx.doi.org/10.1007/s00268-017-4181-6.
PubMed.
43 Lau WY, Lai EC. Modifications of ALPPS - from complex to more
complex or from complex to less complex operations. Hepatobiliary
Pancreat Dis Int. 2017;16(4):346–52. Published online August 22, 2017.
doi: http://dx.doi.org/10.1016/S1499-3872(17)60034-1. PubMed.
44 Linecker M, Stavrou GA, Oldhafer KJ, Jenner RM, Seifert B, Lurje G,
et al. The ALPPS Risk Score: Avoiding Futile Use of ALPPS. Ann Surg.
Review article: Biomedical intelligence Swiss Med Wkly. 2021;151:w20390
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 9 of 10
2016;264(5):763–71. Published online October 18, 2016. doi:
http://dx.doi.org/10.1097/SLA.0000000000001914. PubMed.
45 Eshmuminov D, Tschuor C, Raptis DA, Boss A, Wurnig MC, Sergeant
G, et al. Rapid liver volume increase induced by associating liver parti-
tion with portal vein ligation for staged hepatectomy (ALPPS): Is it ede-
ma, steatosis, or true proliferation? Surgery. 2017;161(6):1549–52. Pub-
lished online April 16, 2017. doi: http://dx.doi.org/10.1016/
j.surg.2017.01.005. PubMed.
46 Wakabayashi G, Cherqui D, Geller DA, Buell JF, Kaneko H, Han HS, et
al. Recommendations for laparoscopic liver resection: a report from the
second international consensus conference held in Morioka. Ann Surg.
2015;261(4):619–29. Published online March 06, 2015. doi:
http://dx.doi.org/10.1097/sla.0000000000001184. PubMed.
47 Fretland AA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kris-
tiansen R, Fagerland MW, et al. Laparoscopic Versus Open Resection
for Colorectal Liver Metastases: The OSLO-COMET Randomized Con-
trolled Trial. Ann Surg. 2018;267(2):199–207. Published online June 29,
2017. doi: http://dx.doi.org/10.1097/SLA.0000000000002353. PubMed.
48 Aghayan DL, Fretland AA, Kazaryan AM, Sahakyan MA, Dagenborg
VJ, Bjørnbeth BA, et al. Laparoscopic versus open liver resection in the
posterosuperior segments: a sub-group analysis from the OSLO-
COMET randomized controlled trial. HPB (Oxford).
2019;21(11):1485–90. Published online April 10, 2019. doi:
http://dx.doi.org/10.1016/j.hpb.2019.03.358. PubMed.
49 Clavien PA, Barkun J. Consensus conference on laparoscopic liver re-
section: a jury-based evaluation. Ann Surg. 2015;261(4):630–1. Pub-
lished online March 06, 2015. doi: http://dx.doi.org/10.1097/
SLA.0000000000001183. PubMed.
50 Abu Hilal M, Aldrighetti L, Dagher I, Edwin B, Troisi RI, Alikhanov R,
et al. The Southampton Consensus Guidelines for Laparoscopic Liver
Surgery: From Indication to Implementation. Ann Surg.
2018;268(1):11–8. Published online October 25, 2017. doi:
http://dx.doi.org/10.1097/SLA.0000000000002524. PubMed.
51 Fruscione M, Pickens R, Baker EH, Cochran A, Khan A, Ocuin L, et al.
Robotic-assisted versus laparoscopic major liver resection: analysis of
outcomes from a single center. HPB (Oxford). 2019;21(7):906–11. Pub-
lished online January 09, 2019. doi: http://dx.doi.org/10.1016/
j.hpb.2018.11.011. PubMed.
52 Seror O. Ablative therapies: Advantages and disadvantages of radiofre-
quency, cryotherapy, microwave and electroporation methods, or how to
choose the right method for an individual patient? Diagn Interv Imaging.
2015;96(6):617–24. Published online May 20, 2015. doi:
http://dx.doi.org/10.1016/j.diii.2015.04.007. PubMed.
53 Loveman E, Jones J, Clegg AJ, Picot J, Colquitt JL, Mendes D, et al.
The clinical effectiveness and cost-effectiveness of ablative therapies in
the management of liver metastases: systematic review and economic
evaluation. Health Technol Assess. 2014;18(7):vii–viii, 1–283. doi:
http://dx.doi.org/10.3310/hta18070. PubMed.
54 Coletti L, Battaglia V, De Simone P, Turturici L, Bartolozzi C, Filipponi
F. Safety and feasibility of electrochemotherapy in patients with unre-
sectable colorectal liver metastases: A pilot study. Int J Surg.
2017;44:26–32. doi: http://dx.doi.org/10.1016/j.ijsu.2017.06.033.
PubMed.
55 Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten
Haken RK. Analysis of radiation-induced liver disease using the Lyman
NTCP model. Int J Radiat Oncol Biol Phys. 2002;53(4):810–21. Pub-
lished online July 04, 2002. doi: http://dx.doi.org/10.1016/
S0360-3016(02)02846-8. PubMed.
56 Petrelli F, Comito T, Barni S, Pancera G, Scorsetti M, Ghidini A; SBRT
for CRC liver metastases. Stereotactic body radiotherapy for colorectal
cancer liver metastases: A systematic review. Radiother Oncol.
2018;129(3):427–34. Published online July 13, 2018. doi:
http://dx.doi.org/10.1016/j.radonc.2018.06.035. PubMed.
57 Lee J, Shin IS, Yoon WS, Koom WS, Rim CH. Comparisons between
radiofrequency ablation and stereotactic body radiotherapy for liver ma-
lignancies: Meta-analyses and a systematic review. Radiother Oncol.
2020;145:63–70. Published online January 11, 2020. doi:
http://dx.doi.org/10.1016/j.radonc.2019.12.004. PubMed.
58 Jackson WC, Tao Y, Mendiratta-Lala M, Bazzi L, Wahl DR, Schipper
MJ, et al. Comparison of Stereotactic Body Radiation Therapy and Ra-
diofrequency Ablation in the Treatment of Intrahepatic Metastases. Int J
Radiat Oncol Biol Phys. 2018;100(4):950–8. doi: http://dx.doi.org/
10.1016/j.ijrobp.2017.12.014. PubMed.
59 Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy
for liver tumours: visualising the future. Lancet Oncol.
2020;21(2):e74–82. Published online February 03, 2020. doi:
http://dx.doi.org/10.1016/S1470-2045(20)30034-6. PubMed.
60 Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et
al.; SARAH Trial Group. Efficacy and safety of selective internal radio-
therapy with yttrium-90 resin microspheres compared with sorafenib in
locally advanced and inoperable hepatocellular carcinoma (SARAH): an
open-label randomised controlled phase 3 trial. Lancet Oncol.
2017;18(12):1624–36. Published online November 07, 2017. doi:
http://dx.doi.org/10.1016/S1470-2045(17)30683-6. PubMed.
61 Morse MA, Hanks BA, Suhocki P, Doan PL, Liu EA, Frost P, et al. Im-
proved time to progression for transarterial chemoembolization com-
pared with transarterial embolization for patients with unresectable he-
patocellular carcinoma. Clin Colorectal Cancer. 2012;11(3):185–90.
Published online January 28, 2012. doi: http://dx.doi.org/10.1016/
j.clcc.2011.11.003. PubMed.
62 Wasan HS, Gibbs P, Sharma NK, Taieb J, Heinemann V, Ricke J, et al.;
FOXFIRE trial investigators; SIRFLOX trial investigators; FOXFIRE-
Global trial investigators. First-line selective internal radiotherapy plus
chemotherapy versus chemotherapy alone in patients with liver metas-
tases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-
Global): a combined analysis of three multicentre, randomised, phase 3
trials. Lancet Oncol. 2017;18(9):1159–71. doi: http://dx.doi.org/
10.1016/S1470-2045(17)30457-6. PubMed.
63 Dutkowski P, De Rougemont O, Müllhaupt B, Clavien PA. Current and
future trends in liver transplantation in Europe. Gastroenterology.
2010;138(3):802–9.e4. doi: http://dx.doi.org/10.1053/j.gas-
tro.2010.01.030. PubMed.
64 Starzl TE. The saga of liver replacement, with particular reference to the
reciprocal influence of liver and kidney transplantation (1955-1967). J
Am Coll Surg. 2002;195(5):587–610. doi: http://dx.doi.org/10.1016/
S1072-7515(02)01498-9. PubMed.
65 Gores GJ. Liver transplantation for malignant disease. Gastroenterol
Clin North Am. 1993;22(2):285–99. Published online June 01, 1993.
PubMed.
66 Penn I. Hepatic transplantation for primary and metastatic cancers of the
liver. Surgery. 1991;110(4):726–34, discussion 734–5. Published online
October 01, 1991. PubMed.
67 Moris D, Tsilimigras DI, Chakedis J, Beal EW, Felekouras E, Ver-
nadakis S, et al. Liver transplantation for unresectable colorectal liver
metastases: A systematic review. J Surg Oncol. 2017;116(3):288–97.
doi: http://dx.doi.org/10.1002/jso.24671. PubMed.
68 Hagness M, Foss A, Line PD, Scholz T, Jørgensen PF, Fosby B, et al.
Liver transplantation for nonresectable liver metastases from colorectal
cancer. Ann Surg. 2013;257(5):800–6. Published online January 31,
2013. doi: http://dx.doi.org/10.1097/SLA.0b013e3182823957. PubMed.
69 Toso C, Pinto Marques H, Andres A, Castro Sousa F, Adam R, Kalil A,
et al.; Compagnons Hépato-Biliaires Group. Liver transplantation for
colorectal liver metastasis: Survival without recurrence can be achieved.
Liver Transpl. 2017;23(8):1073–6. doi: http://dx.doi.org/10.1002/
lt.24791. PubMed.
Review article: Biomedical intelligence Swiss Med Wkly. 2021;151:w20390
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 10 of 10
